Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Antisense oligonucleotide therapeutics(sterna) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Antisense oligonucleotide therapeutics(sterna): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market p
9 min read
Spevatamig Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Spevatamig: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
SQ-22031 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
SQ-22031: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
PT-00114 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
PT-00114: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
PD-1 knockout engineered T cells(West China Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
PD-1 knockout engineered T cells(West China Hospital): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, m
9 min read
Xiaoerreping granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Xiaoerreping granules: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Umiposgene Parvec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Umiposgene Parvec: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
SYH2069 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
SYH2069: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
MZE-782 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
MZE-782: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ELI-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
ELI-002: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
PTR-01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
PTR-01: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Vaccine PvCS N/C/R(Malaria Vaccine and Drug Development Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Vaccine PvCS N/C/R(Malaria Vaccine and Drug Development Center): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensin